Real-World diabetes drug study launches in russia
NCT ID NCT07433192
First seen Feb 26, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This study watches 300 adults with type 2 diabetes who are already taking the drug luseogliflozin (Lusefi®) as part of their normal care. Researchers will track changes in blood sugar, weight, and blood pressure over time to see how effective and tolerable the drug is in real-world settings. No new treatments are given; it simply observes routine medical visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GBUZ hospital
RECRUITINGAnapa, Russia
Conditions
Explore the condition pages connected to this study.